+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • July 2024
  • Region: Global
  • The Business Research Company
  • ID: 5986887
The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $4.24 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 27.7%. The growth in the historic period can be attributed to favorable regulatory frameworks, increased technological advancements, high prevalence of genetic disorders, increased investments, and an increased number of strategic partnerships.

The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $14.52 billion in 2028 at a compound annual growth rate (CAGR) of 28%. The growth during the forecast period can be attributed to expanded therapeutic applications, regulatory changes, increased investment, technological advancements, and global collaboration. Key trends expected in this period include rising demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, the emergence of novel delivery systems, and a greater focus on sustainability and environmental impact.

The increasing prevalence of cancer cases is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, characterized by uncontrolled growth and spread of abnormal cells, is becoming more common due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. CDMOs play a crucial role in combating cancer by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. For example, according to Macmillan Cancer Support, a UK-based charitable organization, the number of people living with cancer in the UK is projected to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing prevalence of cancer cases is fueling the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating on broadening their portfolio by integrating advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system designed for large-scale production of cell-based products. This innovative technology enables 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a new business division providing cell therapy manufacturing services as a CDMO. This new division encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division delivers end-to-end services ranging from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as outlined in a company announcement. It harnesses the company's state-of-the-art PluriMatrix technology to provide advanced cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based company specializing in food and biotechnology, purchased Forge Biologics for $620 million. This acquisition enhances Ajinomoto's worldwide expertise in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, strengthening its current contract development and manufacturing services. Forge Biologics, based in the US, is a contract development and manufacturing organization (CDMO) for gene therapy and a clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that supports the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations provide services tailored to the specific needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs are crucial in speeding up the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services from early-stage development through to commercialization.

The primary product types offered by cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person's cells to treat or prevent disease. These therapies undergo various phases, including phase 1, phase 2, phase 3, and phase 4, and are developed for a range of indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

The cell and gene therapy contract development and manufacturing organization (CDMO) market research report is one of a series of new reports that provides cell and gene therapy contract development and manufacturing organization (CDMO) market statistics, including cell and gene therapy contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (CDMO) market share, detailed cell and gene therapy contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (CDMO) industry. This cell and gene therapy contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Characteristics3. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Trends and Strategies
4. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Size and Growth
5.1. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Segmentation
6.1. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Gene Therapy
  • Gene-Modified Cell Therapy
  • Cell Therapy
6.2. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
6.3. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Rare Diseases
  • Other Indications
7. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Regional and Country Analysis
7.1. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
8.1. Asia-Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
(Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
9.1. China Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
9.2. China Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
10.1. India Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
11.1. Japan Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
11.2. Japan Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
12.1. Australia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
13.1. Indonesia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
14.1. South Korea Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
14.2. South Korea Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
15.1. Western Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
15.2. Western Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
16.1. UK Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
17.1. Germany Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
18.1. France Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
19.1. Italy Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
20.1. Spain Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
21.1. Eastern Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
21.2. Eastern Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
22.1. Russia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
23.1. North America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
23.2. North America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
24.1. USA Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
24.2. USA Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
25.1. Canada Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
25.2. Canada Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
26.1. South America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
26.2. South America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
27.1. Brazil Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
28.1. Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
28.2. Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
29.1. Africa Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Overview
29.2. Africa Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Competitive Landscape and Company Profiles
30.1. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Competitive Landscape
30.2. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Company Profiles
30.2.1. Pfizer Inc
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck & Co. Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Thermo Fisher Scientific Inc
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Novartis AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. FUJIFILM Diosynth Biotechnologies
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Other Major and Innovative Companies
31.1. AGC Biologics
31.2. Ajinomoto Co Inc
31.3. Lonza Group
31.4. Catalent Inc
31.5. Charles River Laboratories International Inc
31.6. Sartorius Stedim Biotech
31.7. Samsung Biologics Co Ltd
31.8. WuXi Biologics
31.9. Recipharm AB
31.10. Almac Group Ltd
31.11. KBI Biopharma
31.12. Rentschler Biopharma
31.13. Bio Elpida
31.14. Oxford BioMedica Plc
31.15. Avid Bioservices Inc
32. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Competitive Benchmarking33. Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market
35. Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Future Outlook and Potential Analysis
35.1 Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market in 2028 - Countries Offering Most New Opportunities
35.2 Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market in 2028 - Segments Offering Most New Opportunities
35.3 Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for cell and gene therapy contract development and manufacturing organization (cdmo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy contract development and manufacturing organization (cdmo) market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product Type: Gene Therapy; Gene-Modified Cell Therapy; Cell Therapy
2) By Phase: Phase 1; Phase 2; Phase 3; Phase 4
3) By Indication: Oncology; Infectious Diseases; Neurological Disorders; Rare Diseases; Other Indications

Key Companies Mentioned: Pfizer Inc; Merck & Co. Inc.; Thermo Fisher Scientific Inc; Novartis AG; FUJIFILM Diosynth Biotechnologies

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc
  • Merck & Co. Inc.
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • FUJIFILM Diosynth Biotechnologies
  • AGC Biologics
  • Ajinomoto Co Inc
  • Lonza Group
  • Catalent Inc
  • Charles River Laboratories International Inc
  • Sartorius Stedim Biotech
  • Samsung Biologics Co Ltd
  • WuXi Biologics
  • Recipharm AB
  • Almac Group Ltd
  • KBI Biopharma
  • Rentschler Biopharma
  • Bio Elpida
  • Oxford BioMedica Plc
  • Avid Bioservices Inc
  • Cell and Gene Therapy Catapult
  • VGXI Inc
  • Genezen Laboratories Inc.
  • Pluri Inc.
  • OmniaBio Inc.

Methodology

Loading
LOADING...

Table Information